glp 1 by lilly GLP-1 analogs, new trend in obesity treatment, become even more effective < Pharma < Article Eli Lilly to seek approval

Visible weight loss typically begins between weeks 4 and 8, with peak results at 12-18 months of consistent use at the therapeutic dose

( , , , )

Semaglutide doesnt cause permanent ovarian damage or premature menopause

mesohyal organic silicon INTRADERMAL MEDICAL SOLUTIONS Treatment of intradermal administration to improve the appearance of the skin giving back its silky touch and its elasticity

Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review

Treasury yield above 4%, Pfizers ~7% dividend yield faces competition from safer returns